RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramTodays announcement is a huge win.
In last post I gave thoughts on target therapeutic popularion
ONC always intended to partner entering into a phase 3. If thats still the case, we have a partnership to look forward to in the near term before a phase 3 mBC is launched.
Acceptance of PFS as a primary trial outcome over OS is also a big win. It dramatically shortens time to marketing approval.
I dont see aquisition happening until the biomarker/protocol failure corrected. It has potential to double overall response rates and percentages of those recieving therapeutic benefit.
Exciting times ahead.